Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Celcuity announced that its Phase III Viktoria-1 clinical trial has successfully achieved the primary endpoint in the Pik3CA mutant patient cohort.

Celcuity announced that its Phase III Viktoria-1 clinical trial has successfully achieved the primary endpoint in the Pik3CA mutant patient cohort.

老虎证券老虎证券2026/05/01 21:10
Show original

Experimental data show that this cohort of patients achieved a clinically significant improvement in progression-free survival.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!